Literature DB >> 24563459

Laparoscopy for diagnosing resectability of disease in patients with advanced ovarian cancer.

Marianne J Rutten1, Mariska M G Leeflang, Gemma G Kenter, Ben Willem J Mol, Marrije Buist.   

Abstract

BACKGROUND: The presence of residual tumour after primary debulking surgery is the most important prognostic factor in patients with advanced ovarian cancer. In up to 60% of cases, residual tumour of more than 1 cm is left behind, stressing the necessity of accurately selecting those patients who should be treated with primary debulking surgery and those who should receive neoadjuvant chemotherapy instead.
OBJECTIVES: To determine if performing an open laparoscopy after the diagnostic work-up of patients suspected of advanced ovarian cancer is accurate in predicting the resectability of disease. SEARCH
METHODS: We searched MEDLINE, EMBASE, The Cochrane Central Register of Controlled Trials (CENTRAL), the Cochrane Register of Diagnostic Test Accuracy Studies, MEDION and ISI Web of Science to February 2013. Furthermore, we checked references of identified primary studies and review articles. SELECTION CRITERIA: We included studies that evaluated the diagnostic accuracy of laparoscopy to determine the resectability of disease in patients who are suspected of advanced ovarian cancer and planned to receive primary debulking surgery. DATA COLLECTION AND ANALYSIS: Two review authors assessed the quality of included studies using QUADAS-2 and extracted data on study and patients' characteristics, index test, target condition and reference standard. Data for two-by-two tables were extracted and summarised graphically. Sensitivity and specificity and negative predictive values were calculated. MAIN
RESULTS: We included seven studies reporting on six cohorts. Between 27% to 64% of included patients per study were positive on laparoscopy (too extensive disease to warrant laparotomy) and between 36% to 73% were negative (disease suitable for debulking laparotomy). Only two studies avoided partial verification bias and provided data to calculate sensitivity and specificity, which did not justify meta-analysis. These two studies had a sensitivity of 0.70 (95% confidence interval (CI) 0.57 to 0.82) and 0.71 (95% CI 0.44 to 0.90); however, the specificity of both studies was 1.00 (95% CI 0.90 to 1.00). In these two studies there were no false positives, i.e. no patients for whom laparoscopy indicated that major surgery would not be successful and should be avoided, whereas, in reality the patient could be successfully operated upon. Negative predictive values (NPV), for those patients who were diagnosed with having not too extensive disease correctly identified were 0.75 (95% CI 0.55 to 0.86) and 0.96 (95% CI 0.56 to 0.99) due to a different prevalence. Although the studies did report sufficient data to calculate NPVs, we judged these estimates too heterogeneous to meta-analyse.Three studies described the development or validation of a prediction model with a clear cut-off for test positivity. Sensitivity and specificity of these prediction models were 0.30 to 0.70 and 0.89 to 1.00, respectively. However, one of these studies suffered from partial verification bias. AUTHORS'
CONCLUSIONS: Laparoscopy is a promising test, but the low number of studies and the differences between the included studies do not allow firm conclusions to be drawn from these data. Due to a difference in prevalence, there is a wide range in negative predictive values between studies. Two studies verified all patients. These imply a high specificity of laparoscopy in diagnosing resectability and have a good sensitivity. Both studies show that the use of criteria for unresectable disease will result in no patients inappropriately unexplored. However, there will still be patients undergoing unsuccessful primary laparotomy. Using a prediction model does not increase the sensitivity and will result in more unnecessarily explored patients, due to a lower specificity.

Entities:  

Mesh:

Year:  2014        PMID: 24563459      PMCID: PMC6457797          DOI: 10.1002/14651858.CD009786.pub2

Source DB:  PubMed          Journal:  Cochrane Database Syst Rev        ISSN: 1361-6137


  20 in total

1.  Concordance of laparoscopic and laparotomic peritoneal cancer index using a two-step surgical protocol to select patients for cytoreductive surgery in advanced ovarian cancer.

Authors:  Martina Aida Angeles; Federico Migliorelli; Mathilde Del; Carlos Martínez-Gómez; Manon Daix; Sarah Bétrian; Erwan Gabiache; Gisèle Balagué; Sophie Leclerc; Eliane Mery; Laurence Gladieff; Gwénaël Ferron; Alejandra Martinez
Journal:  Arch Gynecol Obstet       Date:  2021-01-03       Impact factor: 2.344

Review 2.  Predictors of optimal cytoreduction in patients with newly diagnosed advanced-stage epithelial ovarian cancer: Time to incorporate laparoscopic assessment into the standard of care.

Authors:  Natalia Rodriguez Gómez-Hidalgo; Bertha Alejandra Martinez-Cannon; Alpa M Nick; Karen H Lu; Anil K Sood; Robert L Coleman; Pedro T Ramirez
Journal:  Gynecol Oncol       Date:  2015-03-28       Impact factor: 5.482

Review 3.  Appropriate Recommendations for Surgical Debulking in Stage IV Ovarian Cancer.

Authors:  Jing-Yi Chern; John P Curtin
Journal:  Curr Treat Options Oncol       Date:  2016-01

4.  Current and Future Status of Laparoscopy in Gynecologic Oncology.

Authors:  S Rimbach; K Neis; E Solomayer; U Ulrich; D Wallwiener
Journal:  Geburtshilfe Frauenheilkd       Date:  2014-09       Impact factor: 2.915

5.  Suprarenal lymphadenectomy with nephrectomy for refractory ovarian cancer.

Authors:  Soo Jin Park; Hee Seung Kim
Journal:  Gland Surg       Date:  2021-03

6.  A novel index for preoperative, non-invasive prediction of macro-radical primary surgery in patients with stage IIIC-IV ovarian cancer-a part of the Danish prospective pelvic mass study.

Authors:  Mona Aarenstrup Karlsen; Carsten Fagö-Olsen; Estrid Høgdall; Tine Henrichsen Schnack; Ib Jarle Christensen; Lotte Nedergaard; Lene Lundvall; Magnus Christian Lydolph; Svend Aage Engelholm; Claus Høgdall
Journal:  Tumour Biol       Date:  2016-07-20

Review 7.  Current Recommendations for Minimally Invasive Surgical Staging in Ovarian Cancer.

Authors:  Anna Fagotti; Federica Perelli; Luigi Pedone; Giovanni Scambia
Journal:  Curr Treat Options Oncol       Date:  2016-01

8.  Neoadjuvant chemotherapy for newly diagnosed, advanced ovarian cancer: Society of Gynecologic Oncology and American Society of Clinical Oncology Clinical Practice Guideline.

Authors:  Alexi A Wright; Kari Bohlke; Deborah K Armstrong; Michael A Bookman; William A Cliby; Robert L Coleman; Don S Dizon; Joseph J Kash; Larissa A Meyer; Kathleen N Moore; Alexander B Olawaiye; Jessica Oldham; Ritu Salani; Dee Sparacio; William P Tew; Ignace Vergote; Mitchell I Edelson
Journal:  Gynecol Oncol       Date:  2016-08-08       Impact factor: 5.482

9.  Neoadjuvant Chemotherapy for Newly Diagnosed, Advanced Ovarian Cancer: Society of Gynecologic Oncology and American Society of Clinical Oncology Clinical Practice Guideline.

Authors:  Alexi A Wright; Kari Bohlke; Deborah K Armstrong; Michael A Bookman; William A Cliby; Robert L Coleman; Don S Dizon; Joseph J Kash; Larissa A Meyer; Kathleen N Moore; Alexander B Olawaiye; Jessica Oldham; Ritu Salani; Dee Sparacio; William P Tew; Ignace Vergote; Mitchell I Edelson
Journal:  J Clin Oncol       Date:  2016-08-08       Impact factor: 44.544

10.  Suboptimal cytoreduction in ovarian carcinoma is associated with molecular pathways characteristic of increased stromal activation.

Authors:  Zhenqiu Liu; Jessica A Beach; Hasmik Agadjanian; Dongyu Jia; Paul-Joseph Aspuria; Beth Y Karlan; Sandra Orsulic
Journal:  Gynecol Oncol       Date:  2015-09-06       Impact factor: 5.482

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.